By Cocer Peptides 
kwanaki 15 da suka gabata
DUKKANIN LABARI DA BAYANIN KYAUTATAWA DA AKE BAYAR A WANNAN SHAFIN KAWAI DOMIN WATSA BAYANI NE DA MANUFOFIN ILIMI.
Kayayyakin da aka bayar akan wannan gidan yanar gizon an yi niyya ne kawai don binciken in vitro. Binciken in vitro (Latin: *a cikin gilashi*, ma'ana a cikin gilashin gilashi) ana gudanar da shi a wajen jikin mutum. Waɗannan samfuran ba magunguna ba ne, Hukumar Abinci da Magunguna ta Amurka (FDA) ba ta amince da su ba, kuma dole ne a yi amfani da su don hanawa, magani, ko warkar da duk wani yanayi na likita, cuta, ko cuta. Doka ta haramta shigar da waɗannan samfuran cikin jikin mutum ko dabba ta kowace hanya.
Dubawa
Mazdutide wani sabon magani ne wanda ke aiki azaman agonist biyu na glucagon-kamar peptide-1 (GLP-1) da masu karɓar glucagon. GLP-1 da masu karɓar glucagon suna taka muhimmiyar rawa wajen daidaita tsarin rayuwa a cikin jikin ɗan adam. GLP-1 ana fitar da shi ne da farko ta ƙwayoyin L a cikin hanji, ana fitar da su bayan cin abinci, kuma yana motsa ƙwayar insulin ta hanyar dogaro da glucose yayin da yake hana ƙwayar glucagon, ta haka yana rage matakan glucose na jini. GLP-1 kuma yana rage zubar ciki, yana kara yawan koshi, kuma yana rage cin abinci, ta haka yana taimakawa wajen sarrafa nauyi. Masu karɓar Glucagon da farko suna daidaita ma'aunin glucose na jini. Bayan glucagon ya ɗaure ga mai karɓar sa, yana kunna jerin hanyoyin jigilar sigina don haɓaka glycogenolysis da gluconeogenesis, ta haka yana haɓaka matakan glucose na jini. Mazdutide, a matsayin mai dual agonist, yana samun ka'idojin rayuwa ta hanyar fasaha mai wayo.
Tsarin Aiki
Tsarin Tsarin Tsarin Glucose na Jini
Haɓaka Sirrin Insulin: Bayan ɗaure ga mai karɓar GLP-1, Mazdutide yana kunna hanyoyin siginar ƙasa, gami da hanyar siginar cAMP-PKA. Kunna wannan hanyar yana haɓaka haɓakar ƙwayoyin β-sel na pancreatic zuwa glucose, yana haifar da haɓakar maganganun kwayoyin halittar insulin da haɓaka haɓakar insulin da ɓoyewa. Lokacin da matakan glucose na jini ya tashi, Mazdutide na iya ƙara haɓaka sakin insulin yadda ya kamata, ta haka yana rage matakan glucose na jini. A cikin marasa lafiya da ke da nau'in ciwon sukari na 2, Mazdutide yana haɓaka haɓakar insulin bayan cin abinci ta hanyar wannan hanyar, yana taimakawa daidaita matakan glucose na jini.
Hana ɓoyewar glucagon: Ayyukan Mazdutide akan masu karɓar glucagon shima yana tasiri tasirin glucagon. Ta hanyar ɗaure masu karɓar glucagon, yana hana watsa sigina a cikin ƙwayoyin α pancreatic, yana rage haɗin glucagon da sakin. Wannan yana hana glycogenolysis da gluconeogenesis, rage samar da glucose a tushen kuma yana kara taimakawa wajen rage matakan glucose na jini. Wannan tsari guda biyu na insulin da glucagon yana ba Mazdutide babbar fa'ida a cikin tsarin glucose na jini, yana ba da damar sarrafa madaidaicin matakan glucose na jini da kuma guje wa manyan canje-canje.
Canjin kashi dari daga asali a cikin nauyin jiki akan lokaci. Adadin mahalarta da suka kai ga asarar nauyi.
Tsarin sarrafa nauyi
Tsarin abinci: Mazdutide yana ɗaure ga masu karɓa na GLP-1, suna kunna neurons a cikin cibiyar sarrafa abinci ta hypothalamic. Waɗannan jijiyoyi suna shiga cikin watsa siginar satiety, kuma aikin Mazdutide yana haɓaka waɗannan sigina, ta haka rage cin abinci. Hakanan yana iya yin tasiri kan fitar da hormones na ciki, kamar ghrelin, yana ƙara daidaita ci. A cikin gwaje-gwajen asibiti, mahalarta masu amfani da Mazdutide sun ba da rahoton rage cin abinci da rage cin abinci na yau da kullun, wanda ke haifar da asarar nauyi.
Ƙara yawan kuɗin kuzari: Mazdutide kuma na iya haɓaka asarar nauyi ta hanyar tasiri na makamashin jiki. Bincike ya nuna yana iya kunna ƙwayar adipose mai launin ruwan kasa, yana ƙara yawan aikin thermogenic. Brown adipose tissue yana da wadata a cikin mitochondria kuma yana iya cinye makamashi ta hanyar thermogenesis mara girgiza. Mazdutide na iya tsara hanyoyin siginar da ke da alaƙa don haɓaka bambance-bambance da kunna adipocytes masu launin ruwan kasa, haɓaka ƙarfin su na thermogenic, ta haka yana haɓaka kashe kuzarin jiki da samun asarar nauyi. Mazdutide kuma na iya yin tasiri kan metabolism na farin adipose nama, yana haɓaka jujjuyawar kitse zuwa kitse mai launin ruwan kasa, ƙara haɓaka metabolism na mai da rage yawan kitse.
Tsarin tsari na uric acid
Ka'idar magana ta Gene: A cikin nazarin ta yin amfani da samfurin bera na hyperuricemia, an lura da manyan canje-canje a cikin maganganun wasu mahimman kwayoyin halitta bayan sa hannun Mazdutide. Wadannan canje-canje a cikin maganganun kwayoyin halitta na iya samun raguwa a cikin matakan uric acid ta hanyar daidaita abubuwan da suka faru na haɗin uric acid da kuma shiga cikin matakai irin su glycolipid metabolism da purine metabolism. Ƙwayoyin halittar da aka haɓaka suna haɓaka haɓakar uric acid ko shiga cikin hanyoyin rayuwa waɗanda ke hana haɓakar uric acid, yayin da ƙayyadaddun ƙwayoyin cuta suna rage ƙirƙira na precursors don haɓakar uric acid, ta haka gabaɗayan rage matakan uric acid na jini.
Ka'idojin Hanyar Metabolic: Binciken kwafi na renal ya nuna cewa Mazdutide ya sami wadatar hanyoyin KEGG da yawa da suka haɗa da ɓoyewar bile, tsarin renin-angiotensin, metabolism na histidine, juriya na platinum, layin hematopoietic cell lineages, complement, da coagulation cascade. Tsarin waɗannan hanyoyin na iya yin tasiri a kaikaice na uric acid metabolism. Tsarin hanyar ɓoyewar bile na iya shafar metabolism na bile acid, wanda ke da alaƙa da haɓakar metabolism na lipid. Canje-canje a cikin metabolism na lipid na iya yin tasiri ga samar da uric acid da fitarwa. Tsarin tsarin renin-angiotensin na iya rinjayar aikin hemodynamics na koda da aikin tubular, wanda hakan zai haifar da sake dawowa da fitar da uric acid.
inganci
Tasirin Kula da Glucose
A cikin bazuwar, makafi biyu, gwajin gwaji na asibiti na mataki na 2 a cikin marasa lafiya da ke da nau'in ciwon sukari na 2, Mazdutide ya nuna tasirin sarrafa glucose na jini. Binciken da aka ba da izini ga marasa lafiya da ke da nau'in ciwon sukari na 2 don karɓar 3 MG, 4.5 MG, ko 6 MG na Mazdutide, 1.5 MG na buɗaɗɗen lakabin dulaglutide, ko placebo, kuma an gudanar da allurar subcutaneous na makonni 20. Sakamakon ya nuna cewa daga asali zuwa mako na 20, ma'anar canjin haemoglobin A1c (HbA1c) a cikin kungiyoyin Mazdutide ya kasance daga -1.41% zuwa -1.67%, yayin da rukunin dulaglutide ya canza -1.35% kuma ƙungiyar placebo ta sami canji na 0.03%. Idan aka kwatanta da ƙungiyar placebo, canje-canje a cikin matakan HbA1c a cikin duk ƙungiyoyin kashi na Mazdutide suna da mahimmanci a ƙididdiga (duk P <0.0001). Wannan yana nuna cewa Mazdutide yana da tasiri sosai fiye da placebo wajen rage matakan HbA1c a cikin marasa lafiya da ke da nau'in ciwon sukari na 2, kuma yana kama da ko ma ya fi dulaglutide. Rage matakan HbA1c yana nuna ikon Mazdutide don inganta ingantaccen sarrafa glycemic na dogon lokaci a cikin marasa lafiya, don haka rage haɗarin rikice-rikice na ciwon sukari.
Tasirin asarar nauyi
Mazdutide yana nuna ingantaccen inganci a sarrafa nauyi. A cikin binciken da aka yi niyya ga manya ko masu kiba, makonni 24 na jiyya na Mazdutide sun nuna sakamako mai kyau na asarar nauyi. Manya masu kiba (BMI] ≥24 kg / m²) tare da polyphagia da / ko aƙalla ɗaya daga cikin cututtukan da ke da alaƙa da kiba, ko manya masu kiba (BMI ≥28 kg / m²), An ba da izini bazuwar (3: 1: 3: 1: 3: 1) don karɓar 3mgzdu mako-mako, 5mgzdu, 6mg, 6. magani. Sakamako ya nuna cewa daga asali zuwa mako 24, ma'anar canjin canji a cikin nauyi shine -6.7% (kuskuren daidaitaccen 0.7) a cikin ƙungiyar Mazdutide 3 mg, -10.4% (0.7) a cikin ƙungiyar 4.5 MG, -11.3% (0.7) a cikin ƙungiyar 6 MG, da 1.0% a cikin rukunin 0.7. Idan aka kwatanta da placebo, bambance-bambancen jiyya na Mazdutide a duk ƙungiyoyin kashi sun kasance daga -7.7% zuwa -12.3% (duk P <0.0001). Wannan yana nuna cewa Mazdutide na iya rage nauyin jiki sosai a cikin manya ko masu kiba ta hanyar dogaro da kashi. Wannan asarar nauyi ba wai kawai yana taimakawa inganta yanayin jikin marasa lafiya ba amma mafi mahimmanci yana rage haɗarin cututtuka daban-daban masu alaƙa da kiba, kamar cututtukan zuciya da jijiyoyin jini da ciwon sukari.
Uric acid-ƙananan sakamako
A cikin ƙirar bera na hyperuricemia, Mazdutide ya nuna tasirin rage yawan uric acid. An jawo hyperuricemia a cikin berayen ta hanyar gudanar da baki na adenine da potassium oxinic acid, sannan aka bi da magani tare da allurai daban-daban na Mazdutide. Sakamakon ya nuna cewa ƙungiyoyi masu matsakaici da matsakaici na Mazdutide (0.05 mg / kg da 0.075 mg / kg, ana gudanar da su ta hanyar allurar subcutaneous kowane kwanaki 3) sun rage yawan matakan serum uric acid (SUA) a cikin berayen. Mazdutide kuma ya inganta aikin koda, rage yawan sinadarin creatinine (SCr) da furotin na fitsari (U-Pro), da kuma inganta ilimin cututtukan koda. Wannan yana nuna cewa Mazdutide ba wai kawai yana rage matakan uric acid ba ne kawai amma yana da tasirin kariya daga lalacewar koda ta hanyar hyperuricemia.
Yankunan aikace-aikace
Maganin Nau'in Ciwon Suga Na 2
Ganin ingantaccen ingancin Mazdutide a cikin sarrafa glucose na jini, yana da babban yuwuwar aikace-aikace a cikin kula da nau'in ciwon sukari na 2. A halin yanzu, maganin nau'in ciwon sukari na 2 da farko ya dogara ne akan haɗakar magunguna da yawa don sarrafa matakan glucose na jini da hana faruwar rikice-rikice. A matsayin novel dual receptor agonist, musamman tsarin aiki na Mazdutide yana ba shi damar daidaita glucose metabolism a matakai da yawa, yana ba da sabon zaɓin magani ga marasa lafiya masu ciwon sukari na 2. Idan aka kwatanta da magungunan maganin ciwon sukari na gargajiya, Mazdutide ba wai kawai yana rage matakan glucose na jini yadda ya kamata ba har ma yana ba da fa'idar rage nauyi, wanda ke da mahimmanci musamman ga yawancin masu ciwon sukari na 2 masu kiba ko kiba.
Kiba da kula da kiba
Kiba da kiba sun zama batutuwan kiwon lafiyar jama'a a duniya wanda ke da alaƙa da kamuwa da cututtuka daban-daban. Mahimman tasirin Mazdutide a cikin sarrafa nauyi ya sa ya zama zaɓin magani mai yuwuwa ga masu kiba da masu kiba. Ta hanyar daidaita ci da haɓaka kashe kuzari, Mazdutide na iya taimakawa marasa lafiya masu kiba da kiba su rasa nauyi da haɓaka matsayinsu na rayuwa. Idan aka kwatanta da hanyoyin asarar nauyi na gargajiya kamar cin abinci da motsa jiki, Mazdutide yana ba da zaɓin magani mai inganci, musamman ga waɗanda ke gwagwarmaya don cimma madaidaicin nauyinsu ta hanyar saɓanin rayuwa. Bugu da ƙari, saboda tsarin aikin sa wanda ya haɗa da tsarin tsarin tsarin jiki da yawa, Mazdutide na iya samun tasiri mai kyau akan tsarin zuciya da jijiyoyin jini yayin rage nauyi, ta haka yana rage haɗarin rikice-rikice masu alaƙa da kiba.
Kammalawa
A taƙaice, a matsayin novel agonist dual agonist na GLP-1 da glucagon receptors, Mazdutide yana nuna keɓaɓɓen hanyoyin aiki da ingantaccen inganci a cikin tsarin glucose na jini, sarrafa nauyi, da yuwuwar tsarin uric acid, yana taka muhimmiyar rawa a cikin sarrafa nau'in ciwon sukari na 2, kiba, da yanayin kiba.
Sources
[1] Zhang B, Cheng Z, Chen J, et al. Inganci da Tsaron Mazdutide a cikin Majinyatan Sinawa Masu Ciwon sukari Na 2: Bazuwar, Makafi Biyu, Gwajin Mataki na 2 Mai Sarrafa Wuri[J]. Kula da ciwon sukari, 2024,47 (1): 160-168.DOI: 10.2337 / dc23-1287.
[2] Nalisa DL, Cuboia N, Dyab E, et al. Inganci da amincin Mazdutide akan asarar nauyi tsakanin masu ciwon sukari da marasa ciwon sukari: nazari na yau da kullun da meta-bincike na gwaje-gwajen da aka sarrafa bazuwar[J]. Iyakoki a cikin Ilimin Ilimin Halittu, 2024,15. https://api.semanticscholar.org/CorpusID:267984513
[3] Ji L, Jiang H, Cheng Z, et al. Gwajin gwaji na mazdutide na zamani na 2 a cikin manya masu kiba na kasar Sin ko manya masu kiba[J]. Sadarwar yanayi, 2023,14 (1): 8289.DOI: 10.1038 / s41467-023-44067-4.
[4] Jiang H, Zhang Y, REN Y S. 77-LB: Littafin Glucagon-Kamar Peptide-1 (GLP-1R) da Glucagon (GCGR) Mai karɓar Dual Agonist, Mazdutide (IBI362), Yana haɓaka Hyperuricemia a cikin Berayen Hyperuricemic [J]. Ciwon sukari, 2023. https://api.semanticscholar.org/CorpusID:259452040
Samfura akwai don amfani da bincike kawai:
